Want to see CLYM full AI Analyst Report?
Top Page
Climb Bio
(NASDAQ:CLYM)
Select Model
Select Model
Rating:52Neutral
Price Target:
$11.00
▼(-31.59% Downside)
Action:Reiterated
Date:10/07/26
The score is primarily constrained by weak operating fundamentals (no revenue, ongoing losses, and continued cash burn) despite a strong balance sheet. Technicals also weigh on the rating due to a clear downtrend, while recent positive clinical milestones provide a meaningful, but not overriding, offset. Valuation is difficult to justify on conventional metrics given the negative P/E and no dividend yield.
Positive Factors
Strong capitalization and very low leverage
Extremely low leverage and a materially larger equity base provide financial flexibility for continued research and development. This capitalization reduces refinancing pressure and gives Climb Bio more capacity to advance its pipeline before potential commercial revenues emerge.
Negative Factors
No commercial revenue
The absence of revenue means Climb Bio has not yet demonstrated commercial traction or an operating business model that funds itself. Its investment case remains dependent on clinical progress and eventual product approval, leaving near-term financial performance disconnected from pipeline spending.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong capitalization and very low leverage
Extremely low leverage and a materially larger equity base provide financial flexibility for continued research and development. This capitalization reduces refinancing pressure and gives Climb Bio more capacity to advance its pipeline before potential commercial revenues emerge.
Read all positive factors
Climb Bio (CLYM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$620.31M
Dividend YieldN/A
Average Volume (3M)1.33M
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue GrowthN/A
EPS Growth-19.29%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.83
Shares Outstanding57,436,256
10 Day Avg. Volume943,301
30 Day Avg. Volume1,333,265
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.93K
Enterprise Value/Ebitda-13.67
Forecast
1Y Price Target
$28.10Price Target Upside74.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.79
Revenue Forecast (FY)N/A
Climb Bio Business Overview & Revenue Model
Company Description
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is ...
Climb Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -68.00K | -97.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -59.35M | -59.75M | -30.36M | -35.12M | -45.24M | -47.48M |
| Net Income | -57.62M | -59.85M | -73.90M | -35.12M | -45.24M | -47.48M |
Balance Sheet | ||||||
| Total Assets | 246.29M | 167.74M | 217.19M | 110.47M | 134.99M | 173.24M |
| Cash, Cash Equivalents and Short-Term Investments | 183.12M | 101.08M | 150.92M | 106.80M | 123.57M | 136.48M |
| Total Debt | 1.31M | 541.00K | 532.00K | 349.00K | 480.00K | 0.00 |
| Total Liabilities | 6.75M | 7.27M | 5.31M | 2.87M | 6.28M | 6.04M |
| Stockholders Equity | 239.55M | 160.47M | 211.88M | 107.60M | 128.72M | 167.20M |
Cash Flow | ||||||
| Free Cash Flow | -53.07M | -54.54M | -15.56M | -20.60M | -37.37M | -36.07M |
| Operating Cash Flow | -52.70M | -54.36M | -15.56M | -20.60M | -37.37M | -36.07M |
| Investing Cash Flow | -29.42M | 2.83M | -121.09M | 68.98M | 34.44M | -114.97M |
| Financing Cash Flow | 103.69M | -21.00K | 130.73M | 841.00K | 0.00 | 177.23M |
Climb Bio Technical Analysis
Negative
16.08
Price Trends
13.42
Negative
12.95
Negative
10.22
Positive
Market Momentum
-0.76
Negative
40.76
Neutral
67.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLYM, the sentiment is Negative. The current price of 16.08 is above the 20-day moving average (MA) of 10.84, above the 50-day MA of 13.42, and above the 200-day MA of 10.22, indicating a neutral trend. The MACD of -0.76 indicates Negative momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 67.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLYM.
Climb Bio Risk Analysis
Climb Bio disclosed 72 risk factors in its most recent earnings report. Climb Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Climb Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $460.90M | -5.15 | -23.64% | ― | -76.20% | 52.86% | |
52 Neutral | $620.31M | -13.10 | -31.79% | ― | ― | -19.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $289.94M | 2.36 | -38.12% | ― | 30.47% | ― | |
48 Neutral | $112.16M | -3.86 | -154.32% | ― | ― | 84.80% | |
48 Neutral | $44.41M | -1.10 | 248.50% | ― | ― | 36.06% | |
42 Neutral | $71.00M | -3.89 | -50.17% | ― | ― | 70.27% |
* Healthcare Sector Average
CLYM
Climb Bio
10.87
8.88
446.23%
AGEN
Agenus
6.40
2.22
53.11%
HURA
TuHURA Biosciences
2.09
-0.15
-6.50%
OVID
Ovid Therapeutics
2.47
0.91
58.33%
CGTX
Cognition Therapeutics
0.75
-0.95
-56.12%
TVGN
Tevogen Bio Holdings
6.44
-25.36
-79.75%
Climb Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data
Positive
Sep 3, 2026
On September 3, 2026, Climb Bio reported positive initial Phase 1 data for CLYM116, its anti-APRIL monoclonal antibody, showing a roughly 29-day half-life, near-complete APRIL suppression, and 60-75% reductions in IgA and Gd-IgA1 levels for 12 wee...
Business Operations and StrategyProduct-Related Announcements
Climb Bio Advances Phase 2 Renal Disease Trial
Positive
Aug 14, 2026
On August 13, 2026, Beijing Mabworks Biotech Co., Ltd. and Climb Bio, Inc. reported that the first patient with immunoglobulin A nephropathy was dosed in a Phase 2 clinical trial in China. This milestone marks a key advancement in their joint drug...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.